Over $100B in savings? Why the incoming Humira biosimilars will take time to catch on

Endpoints editor and founder John Carroll sat down the Catalent CEO Alessandro Maselli to talk about what’s ahead in 2023. Right or wrong, this covers all the big issues faced by biopharma. This transcript has been edited for brevity and clarity. I think 2022 had to be one of the worst years ever…#johncarroll #catalent #alessandromaselli #federalreserve #unlock

Source: Reuters: Health - January 30, 2023 Category: Consumer Health News Source Type: news